03.03.26 -- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real

Evaluate a platform designed for evolving workflows. Explore how flexible platforms manage diverse inputs and parameters to maintain scalability and efficiency as your therapy moves toward the clinic.

Low-shear, closed-system media exchange in iPSC differentiation is vital for scalability. This study compares automated centrifugation to gravity sedimentation, showing equivalent or superior differentiation outcomes.

Efficiently scale your MSC therapy manufacturing with closed systems. Learn how a dual-component media kit streamlines automation, reduces variability, and ensures seamless scale-up with minimal optimization.

Is CAR heterogeneity stalling your progress? New single-cell data indicates spatial organization and cell structure directly influence the potency and behavior of your CAR T cell therapies.

Cytotoxic compounding requires rigorous safety protocols. Protect your operators and products with these techniques and technologies to prevent harmful exposure.

Delve into the details of several platform technologies currently being developed and implemented to support effective, large-scale production of viral vectors that meet set quality attributes.

Prioritizing high-quality component design and unwavering manufacturing excellence can mitigate risks, ensure long-term container closure integrity, and avoid the costly delays associated with non-compliance.

Achieving high-quality viral vectors demands rigorous control over contaminants. See how enzymatic approaches can significantly reduce nucleic acid impurities in your manufacturing processes.

Investigate an improved cartridge for the electroporation of complex cargos into large volumes of T cells. Discover how to achieve reliable, robust, and efficient delivery of complex, clinically relevant cargos.

Evaluate the critical process considerations and custom engineering required to handle temperature-sensitive and high-viscosity pharmaceutical materials.